Cargando…

Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy

Lymphocyte depletion chemotherapy CD19-targeted chimeric antigen receptor-modified T (CAR-T) cell immunotherapy is an innovative approach for the treatment of refractory or relapsed B-cell malignancies. This method also has the occurrence of infection, and there has been no systematic analysis of in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Zhilin, Lian, Yu, Ti, Juanjuan, Ren, Ruirui, Ma, Liangming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997630/
https://www.ncbi.nlm.nih.gov/pubmed/36728516
http://dx.doi.org/10.1097/CAD.0000000000001485
_version_ 1784903296111083520
author Gao, Zhilin
Lian, Yu
Ti, Juanjuan
Ren, Ruirui
Ma, Liangming
author_facet Gao, Zhilin
Lian, Yu
Ti, Juanjuan
Ren, Ruirui
Ma, Liangming
author_sort Gao, Zhilin
collection PubMed
description Lymphocyte depletion chemotherapy CD19-targeted chimeric antigen receptor-modified T (CAR-T) cell immunotherapy is an innovative approach for the treatment of refractory or relapsed B-cell malignancies. This method also has the occurrence of infection, and there has been no systematic analysis of infectious complications. In our study, we intend to analyze the infection in patients between day 0 and day 90 by analyzing the data of 40 patients who received CD19 CAR-T cell therapy collected in our hospital. We assessed risk factors for infection before and after treatment using Poisson and Cox regression, respectively. A cohort study was used, including patients with acute lymphocytic leukemia, chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. 40 patients were infected for the first time occurred at a median of 6 days after CAR-T cell infusion, and 8 (20%) had 10 infections within 28 days after CAR-T cell infusion, on days 29 and 29. The infection density between 90 days was lower at 0.67. This resulted in an infection density of 1.19 infections per 100 days. Two patients (5%) developed invasive fungal infections and two patients (5%) developed life-threatening or fatal infections. In an adjusted model for baseline characteristics, patients with ALL, ≥4 prior antitumor regimens, and receiving the highest CAR-T cell dose had higher infection densities at 28 days. The incidence of infection was comparable to that observed in clinical trials of salvage associated with infection after CAR-T cell infusion.
format Online
Article
Text
id pubmed-9997630
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-99976302023-03-09 Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy Gao, Zhilin Lian, Yu Ti, Juanjuan Ren, Ruirui Ma, Liangming Anticancer Drugs Clinical Reports Lymphocyte depletion chemotherapy CD19-targeted chimeric antigen receptor-modified T (CAR-T) cell immunotherapy is an innovative approach for the treatment of refractory or relapsed B-cell malignancies. This method also has the occurrence of infection, and there has been no systematic analysis of infectious complications. In our study, we intend to analyze the infection in patients between day 0 and day 90 by analyzing the data of 40 patients who received CD19 CAR-T cell therapy collected in our hospital. We assessed risk factors for infection before and after treatment using Poisson and Cox regression, respectively. A cohort study was used, including patients with acute lymphocytic leukemia, chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. 40 patients were infected for the first time occurred at a median of 6 days after CAR-T cell infusion, and 8 (20%) had 10 infections within 28 days after CAR-T cell infusion, on days 29 and 29. The infection density between 90 days was lower at 0.67. This resulted in an infection density of 1.19 infections per 100 days. Two patients (5%) developed invasive fungal infections and two patients (5%) developed life-threatening or fatal infections. In an adjusted model for baseline characteristics, patients with ALL, ≥4 prior antitumor regimens, and receiving the highest CAR-T cell dose had higher infection densities at 28 days. The incidence of infection was comparable to that observed in clinical trials of salvage associated with infection after CAR-T cell infusion. Lippincott Williams & Wilkins 2023-04 2023-01-04 /pmc/articles/PMC9997630/ /pubmed/36728516 http://dx.doi.org/10.1097/CAD.0000000000001485 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Clinical Reports
Gao, Zhilin
Lian, Yu
Ti, Juanjuan
Ren, Ruirui
Ma, Liangming
Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy
title Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy
title_full Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy
title_fullStr Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy
title_full_unstemmed Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy
title_short Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy
title_sort therapeutic efficacy and infectious complications of cd19-targeted chimeric antigen receptor-modified t cell immunotherapy
topic Clinical Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997630/
https://www.ncbi.nlm.nih.gov/pubmed/36728516
http://dx.doi.org/10.1097/CAD.0000000000001485
work_keys_str_mv AT gaozhilin therapeuticefficacyandinfectiouscomplicationsofcd19targetedchimericantigenreceptormodifiedtcellimmunotherapy
AT lianyu therapeuticefficacyandinfectiouscomplicationsofcd19targetedchimericantigenreceptormodifiedtcellimmunotherapy
AT tijuanjuan therapeuticefficacyandinfectiouscomplicationsofcd19targetedchimericantigenreceptormodifiedtcellimmunotherapy
AT renruirui therapeuticefficacyandinfectiouscomplicationsofcd19targetedchimericantigenreceptormodifiedtcellimmunotherapy
AT maliangming therapeuticefficacyandinfectiouscomplicationsofcd19targetedchimericantigenreceptormodifiedtcellimmunotherapy